Immunotherapy in indolent Non-Hodgkin's Lymphoma. | Leuk Res Rep;17: 100325, 2022. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Immunotherapy in indolent Non-Hodgkin's Lymphoma.

Amhaz, Ghid; Bazarbachi, Ali; El-Cheikh, Jean.

Affiliation

Amhaz G; Division of hematology-oncology, American University of Beirut Medical Center, Beirut, Lebanon.
Bazarbachi A; Division of hematology-oncology, American University of Beirut Medical Center, Beirut, Lebanon.
El-Cheikh J; Division of hematology-oncology, American University of Beirut Medical Center, Beirut, Lebanon.

Leuk Res Rep ; 17: 100325, 2022.

Article in En | MEDLINE | ID: mdl-35663281

Key words

Immunotherapy; Mechanism of resistance; Monoclonal antibodies; Non-hodgkin lymphoma; Rituximab

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Leuk Res Rep Year: 2022 Document type: Article Affiliation country: Lebanon Country of publication: United kingdom

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Leuk Res Rep Year: 2022 Document type: Article Affiliation country: Lebanon Country of publication: United kingdom